4/A: Amicus Therapeutics Executive Corrects Stock Ownership Reporting After PRSU Award Vesting

David Michael Clark, Chief People Officer at Amicus Therapeutics, amends a previous SEC Form 4 filing to accurately reflect stock acquisitions from a performance-based restricted stock unit (PRSU) award and correct holdings after tax withholdings.

Summary

• David Michael Clark, Chief People Officer of Amicus Therapeutics, filed an amended Form 4 with the SEC to correct a previous filing regarding changes in beneficial ownership.
• The amendment addresses the acquisition of 13,684 shares granted on January 9, 2024, related to the achievement of the 2021 PRSU TSR goal.
• The original Form 4, filed on January 11, 2024, inadvertently excluded these shares and reported incorrect holdings following shares being withheld for taxes.
• The amended form also reflects the disposal of 8,614 shares on January 9, 2024, at a price of $13.65 per share, presumably for tax obligations.
• Following these transactions, Clark directly owns 271,775 shares of Amicus Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previous filing, indicating standard corporate governance procedures. There is no indication of positive or negative sentiment, but the correction itself is a positive sign of transparency.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with securities regulations.

Stakeholder Impact

• The correction of the filing ensures accurate information for shareholders regarding insider ownership.

Key Dates